Status:

UNKNOWN

Retrospective Chart Review of Treataprost Added to Antibiotic Treatment in Patients With Chronic Prostatitis

Lead Sponsor:

GMG Grand Medical

Collaborating Sponsors:

Gama CRO Tıbbi İlaç Araştırma Org.Tic.Ltd.Şti

Conditions:

Quality of Life

Infection, Bacterial

Eligibility:

MALE

18-79 years

Brief Summary

Multicenter, Retrospectivecohort study in patients with Chronic Prostatitis, Chronic Bacterial Prostatitis (Category II) and Chronic Pelvic Pain Syndrome (Category IIIA, IIIB) and 140 patients without...

Detailed Description

This study will be conducted in Patients with Confirmed Chronic Prostatitis and the datas of these patients will be recorded. In real clinical practice, the data of patients who received Treataprost ...

Eligibility Criteria

Inclusion

  • Patients must be ≥ 18 years old and male.
  • The participant must be willing and competent to give written informed consent. If the subject is unable to consent on his behalf, a legally acceptable representative (ie, acceptable to the International Council for Harmonization \[ICH\] and local law as appropriate) must give informed consent on his behalf.
  • Chronic Prostatitis, Chronic Bacterial Prostatitis (Category II) and Chronic Pelvic Pain Syndrome (Category IIIA, IIIB) diagnosed with standard antibiotic therapy with NSAID and antibiotic therapy with NSAID together with Treataprost patients

Exclusion

  • In patients with Chronic Prostatitis, Chronic Bacterial Prostatitis (Category II) and Chronic Pelvic Pain Syndrome (Category IIIA, IIIB) not receiving any treatment
  • For Chronic Prostatitis, Chronic Bacterial Prostatitis (Category II) and Chronic Pelvic Pain Syndrome (Category IIIA, IIIB) taking an herbal preparation other than Treataprost in addition to standard antibiotic therapy and NSAID
  • Patients who have participated in any clinical trial and received an investigational product
  • Patients who did not give written informed consent

Key Trial Info

Start Date :

April 15 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

October 15 2023

Estimated Enrollment :

140 Patients enrolled

Trial Details

Trial ID

NCT05306314

Start Date

April 15 2022

End Date

October 15 2023

Last Update

April 1 2022

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

18 Mart University Faculty of Medicines

Çanakkale, Turkey (Türkiye), 17020

2

TR Ministry of Health Eskişehir City Hospital

Eskişehir, Turkey (Türkiye), 26080

3

Süleyman Demirel University Faculty of Medicines

Isparta, Turkey (Türkiye), 32260

4

Manisa Celal Bayar University Hafsa Sultan Hospital

Manisa, Turkey (Türkiye), 45030